InvestorsHub Logo
Followers 4
Posts 175
Boards Moderated 0
Alias Born 11/12/2013

Re: None

Thursday, 12/14/2017 1:22:53 AM

Thursday, December 14, 2017 1:22:53 AM

Post# of 12450
Health Canada commits to a 30-day default, review period for authorization. That is, if Health Canada does not issue a Non Satisfactory Notice, during the review period, the trial may proceed on the basis of default authorization. Health Canada has an administrative 7-day review target for comparative bioavailability trials, and some Phase I trials in healthy humans volunteers. So latest next week for montelukast trial.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IGXT News